Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
Revenue of Elanco Animal Health Incorporated (ELAN)
Revenue in 2023 (TTM): $4.42 B
According to Elanco Animal Health Incorporated's latest financial reports the company's current revenue (TTM) is $4.42 B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Elanco Animal Health Incorporated
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $4.42 B | $2.49 B | $945 M | $-1,195,000,000 | $-1,231,000,000 |
| 2022 | $4.42 B | $2.51 B | $886 M | $-66,000,000 | $-74,000,000 |
| 2021 | $4.77 B | $2.63 B | $853 M | $-567,000,000 | $-472,000,000 |
| 2020 | $3.27 B | $1.61 B | $461.4 M | $-672,000,000 | $-560,100,000 |
| 2019 | $3.07 B | $1.6 B | $543 M | $78.2 M | $67.9 M |
| 2018 | $3.07 B | $1.49 B | $640 M | $114.1 M | $86.5 M |
| 2017 | $2.89 B | $1.4 B | $835.9 M | $-232,600,000 | $-310,700,000 |
| 2016 | $2.91 B | $1.5 B | $540.4 M | $-22,400,000 | $-47,900,000 |
| 2015 | $2.91 B | $1.38 B | $505.6 M | $-259,500,000 | $-210,800,000 |